Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00794-23Source: DataRank Database

Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis is a research paper published in Antimicrobial Agents and Chemotherapy (2023). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 1.52)OA: hybridTopics (90)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Belén P. Solans ORCID,Anneke C. Hesseling ORCID,Jana Winckler ORCID,H. Simon Schaaf ORCID,Heather R. Draper

Live enrichment

PubMed:38112526 PMC:PMC10777824 OpenAlex:https://openalex.org/W4389948321

Bill and Melinda Gates Foundation

Grant: OPP1191117

HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development

Grant: R01HD083047, AI068632

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: UM1 AI068634, UM1 AI068636, UM1 AI106701, U01 AI068632

NIAID NIH HHS

Grant: UM1 AI068636

NIAID NIH HHS

Grant: UM1 AI068634

NIAID NIH HHS

Grant: UM1 AI106701

NIAID NIH HHS

Grant: UM1 AI068632

NICHD NIH HHS

Grant: R01 HD083047

NIAID NIH HHS

Grant: U01 AI068632

National Institutes of Health

Grant: 3UM1AI106701-12S1

AIDS Clinical Trial Group Laboratory Center

National Institutes of Health

Grant: 3U01AI068632-04S3

International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group

National Institutes of Health

Grant: 5R01HD083047-03

Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment

National Institutes of Health

Grant: 5UM1AI068634-09

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)

National Institutes of Health

Grant: 3UM1AI068636-19SC

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

FWCI

1.52

Citation Percentile

0.8%

Citation Trend

2024

2025

hybridLicense: cc-by

journalhttps://journals.asm.org/doi/pdf/10.1128/aac.00794-23?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00794-23?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.00794-23

journalhttps://doi.org/10.1128/aac.00794-23

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38112526

Fields of Study

Tuberculosis Research and EpidemiologyPneumonia and Respiratory InfectionsPneumocystis jirovecii pneumonia detection and treatment0303 health sciences03 medical and health sciencesAdolescentChildChild, PreschoolHumansClofazimineHIV InfectionsRifampinTuberculosis, Multidrug-Resistant

MeSH Terms

AdolescentAdultAntitubercular AgentsChildChild, PreschoolClofazimineHumansRifampinHIV InfectionsTuberculosis, Multidrug-Resistant

Keywords

ClofazimineMedicinePharmacokineticsRegimenDosingPopulationCohortQT intervalQuinidinePharmacologyInternal medicineLeprosyImmunologyTuberculosisPediatricsQt ProlongationPediatric AIDSHIV InfectionsRifampin (mesh)Preschool (mesh)0605 Microbiology (for)Tuberculosis, Multidrug-Resistant32 Biomedical and Clinical Sciences (for-2020)ChildPediatric3214 Pharmacology and Pharmaceutical Sciences (for-2020)Humans (mesh)3 Good Health and Well Being (sdg)3107 Microbiology (for-2020)Pharmacology and Pharmaceutical SciencesMultidrug-ResistantInfection (hrcs-hc)Infectious DiseasesMedical Microbiology6.1 PharmaceuticalsChild, PreschoolClofazimine (mesh)HIV/AIDSRifampinInfectionAdolescentChild (mesh)610HIV Infections (mesh)MicrobiologyEmerging Infectious Diseases (rcdc)Rare Diseases (rcdc)Rare DiseasesPediatric AIDS (rcdc)HumansPreschoolPediatric (rcdc)HIV/AIDS (rcdc)6.1 Pharmaceuticals (hrcs-rac)Biomedical and Clinical Sciences1115 Pharmacology and Pharmaceutical Sciences (for)Adolescent (mesh)1108 Medical Microbiology (for)3207 Medical microbiology (for-2020)Emerging Infectious DiseasesGood Health and Well BeingInfectious Diseases (rcdc)Multidrug-Resistant (mesh)Microbiology (science-metrix)Sexually Transmitted InfectionsTuberculosis (rcdc)Sexually Transmitted Infections (rcdc)

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being